Bear Lake Dialysis Center is a medicare approved dialysis facility center in Montpelier, Idaho and it has 7 dialysis stations. It is located in Bear Lake county at 164 S Fifth St, Montpelier, ID, 83254. You can reach out to the office of Bear Lake Dialysis Center at (208) 847-4325. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Bear Lake Dialysis Center has the following ownership type - Non-Profit. It was first certified by medicare in June, 2006. The medicare id for this facility is 131316 and it accepts patients under medicare ESRD program.
| Name | Bear Lake Dialysis Center |
|---|---|
| Location | 164 S Fifth St, Montpelier, Idaho |
| No. of Dialysis Stations | 7 |
| Medicare ID | 131316 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 164 S Fifth St, Montpelier, Idaho, 83254 | |
| (208) 847-4325 | |
| Not Available |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago
| NPI Number | 1740370626 |
| Doing Business As | Bear Lake County Memorial Hospital |
| Address | 164 S 5th St Montpelier, Idaho, 83254 |
| Phone Number | (208) 847-4412 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 5 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 9 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 73 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Pediatic patients getting regular hemodialysis at the center | 1 |
| Pediatric patient months included in in Kt/V greater than or eqaul to 1.2 | 11 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Bear Lake Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 10 |
| Hypercalcemia patient months | 85 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 11 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 18 |
| Patient months included in arterial venous fistula and catheter summaries | 89 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 90 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 4 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 8 |
| Hospitalization Rate: Upper Confidence Limit |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).
BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.
At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.
Researchers at the University of Utah Health and University of Illinois at Chicago have identified brain circuitry differences that might be associated with suicidal behavior in individuals with mood disorders.
Australian researchers have potentially created a ‘world-first' malaria vaccine that could save millions of lives. According to Professor Michael Good, of Griffith University in Queensland, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.
› Verified 9 days ago